Alan W. Dunton
Alan W. Dunton's purchase track record
Alan W. Dunton has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/13/2025 | PTN | $4.00M | +73.0% | +445.0% | +14.2% |
| 12/14/2023 | CRMD | $20K | +21.2% | +41.4% | +15.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Palatin Reports Q4 2026 Results With Lower Losses. Palatin Technologies released its fiscal year 2026 financial results, reporting a Q4 loss of $1.11 per share, an improvement from the $2.73 loss in the same period last year. The company also reported sales of $300,770 for the quarter. This update provides the latest financial snapshot for the stock, which is currently trading near its 52-week low.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Oragenics (OGEN) noted in after‑market health‑care stock activity. OGEN was listed among twelve health‑care companies that showed price movement in Friday’s after‑market session, according to Benzinga. The mention highlights recent trading activity outside regular hours, which can influence short‑term sentiment. The stock is currently near its $0.58 support level and its RSI of about 40 reflects modest momentum.
Transaction History
| CRMD | ▲ Buy | Grant | 30,453 | $0 | 1/26/2026 | View on chart |
| CRMD | ▲ Buy | Option Exercise | 20,000 | $81K | 12/30/2025 | View on chart |
| CRMD | ▼ Sell | Open Market | 20,000 | $260K | 12/30/2025 | View on chart |
| PTN | ▲ Buy | Grant | 1,000 | $0 | 12/9/2025 | View on chart |
| PTN | ▲ Buy | Grant | 1,000 | $0 | 12/9/2025 | View on chart |
| CRMD | ▲ Buy | Option Exercise | 10,000 | $36K | 9/12/2025 | View on chart |
| CRMD | ▼ Sell | Open Market | 10,000 | $131K | 9/12/2025 | View on chart |
| PTN | ▲ Buy | Open Market | 200 | $4.0M | 6/13/2025 | View on chart |
| CRMD | ▲ Buy | Grant | 25,000 | $0 | 1/17/2025 | View on chart |
| OGEN | ▼ Sell | Open Market | 66 | $24 | 12/6/2024 | View on chart |
| PTN | ▲ Buy | Grant | 12,000 | $0 | 7/15/2024 | View on chart |
| CRMD | ▲ Buy | Open Market | 3,000 | $10K | 12/15/2023 | View on chart |
| CRMD | ▲ Buy | Open Market | 3,000 | $10K | 12/14/2023 | View on chart |
| PTN | ▼ Sell | Open Market | 199 | $494 | 12/4/2023 | View on chart |
| PTN | ▼ Sell | Open Market | 1 | $2 | 12/4/2023 | View on chart |
| OGEN | ▲ Buy | Grant | 25,000 | $0 | 8/8/2023 | View on chart |
| PTN | ▲ Buy | Grant | 10,000 | $0 | 6/20/2023 | View on chart |
| CRMD | ▲ Buy | Grant | 3,000 | $13K | 5/17/2023 | View on chart |
| PTN | ▼ Sell | Open Market | 200 | $594 | 12/21/2022 | View on chart |
| PTN | ▲ Buy | Grant | 73,000 | $0 | 6/22/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
CRMD: No direct news in the last week
Recent headlines involve Actinium Pharmaceuticals, not CorMedix Inc. There are no events that directly affect CRMD’s operations or market position. Investors can continue to monitor CRMD’s own performance and broader market conditions.
CRMD: No direct news in the last week. Recent headlines involve Actinium Pharmaceuticals, not CorMedix Inc. There are no events that directly affect CRMD’s operations or market position. Investors can continue to monitor CRMD’s own performance and broader market conditions.